alexa Membranous Expression Of PanCD66, CD66 A, CD66 B, And CD66 C And Their Clinical Impact In Acute Leukemia
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

International Conference on Hematology and Oncology
June 29-July 01, 2017 Bangkok, Thailand

Nahla AB Abdulateef
Laboratory and Blood Bank Department, KSA
Posters & Accepted Abstracts: J Blood Disord Transfus
DOI: 10.4172/2155-9864-C1-026
Abstract
CD66 and its isoforms modulate several physiologic processes and have a role in aggressiveness of malignancies. We aimed to investigate the expression of pan CD66, CD66 a, b, and c and their clinical implication in acute leukaemia. This study included 85 cases, 50 AML, 33 ALL and 2 mixed lineage leukaemia cases from King Abdullah Medical City, Saudi Arabia. PanCD66, CD66 a, CD66 b and CD66 c were detected by flowcytometry at diagnosis and panCD66 was reanalysed at day28. The expression rate of panCD66 and CD66 c was 51.8% in B-ALL and was significantly correlated with the BCR/ABL gene, P-value 0.037. CD66 a was detected in 11.1% of B-ALL cases and was significantly associated with shorter overall survival (OS), P-value 0.045. In AML, the expression rates were 40%, 28% and 32% for panCD66, CD66 b and CD66 c respectively. CD66b was significantly correlated with favourable cytogenetics and prolonged OS, with P-values of 0.001 and 0.025, respectively. CD66 c was correlated with CD25 positivity, with a P-value of 0.003. The expression levels of panCD66 at diagnosis and day 28 were significantly correlated, with a P-value of <0.0001. Accordingly, pan CD6 6can be added to the panel for MRD. CD66c is a suitable target for monoclonal antibody therapy in B-ALL and AML. However large-scale studies are needed to verify their association with cytogenetics, CD25 expression and survival.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version